Sign In
Buy LLY
$1,125.38
+42.15 (+3.89%)
At Close: Jun 04, 2026
Eli Lilly shares slide despite weight-loss drug boost as company trims 2025 profit outlook
09:53am, Thursday, 01'st May 2025
Eli Lilly and Co (NYSE:LLY) shares fell as much as 7.7% at the open on Thursday after the drugmaker cut its 2025 profit forecast, overshadowing booming sales of its blockbuster weight-loss drugs. The
Eli Lilly CEO David Ricks on tariffs: We favor carrots, not sticks
09:20am, Thursday, 01'st May 2025
Eli Lilly chairman and CEO David Ricks discusses the potential impact of tariffs.
Eli Lilly CEO says company can help 'respond' to national security concerns around essential drugs as tariffs loom
09:11am, Thursday, 01'st May 2025
Eli Lilly CEO Dave Ricks said the drugmaker can help "respond" to national security concerns around cheaper essential medicines as pharmaceutical-specific tariffs loom. The Trump administration has
Eli Lilly (LLY) Q1 Earnings Lag Estimates
08:55am, Thursday, 01'st May 2025
Eli Lilly (LLY) came out with quarterly earnings of $3.34 per share, missing the Zacks Consensus Estimate of $3.52 per share. This compares to earnings of $2.58 per share a year ago.
Eli Lilly CEO David Ricks on Q1 results, weight loss drug competition and status of weight-loss pill
08:08am, Thursday, 01'st May 2025
Eli Lilly chairman and CEO David Ricks joins 'Squawk Box' to discuss the company's quarterly earnings results, weight loss drug demand and competition, status of the company's weight loss drug pill, p
Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds
07:45am, Thursday, 01'st May 2025
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
Eli Lilly Stock Slips as Lowered Profit Outlook Outweighs Solid Q1 Results
07:31am, Thursday, 01'st May 2025
Shares of Eli Lilly (LLY) fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that came in above analysts' expectations.
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal
06:59am, Thursday, 01'st May 2025
Eli Lilly topped first-quarter earnings and revenue estimates. The drugmaker said sales of weight loss drug Zepbound and diabetes treatment Mounjaro spiked in the first quarter.
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum
06:45am, Thursday, 01'st May 2025
Revenue in Q1 2025 increased 45% to $12.73 billion driven by volume growth from Mounjaro and Zepbound. Pipeline progress included positive Phase 3 trial results for orforglipron (small molecule oral G
Eli Lilly Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
02:43am, Thursday, 01'st May 2025
Eli Lilly and Company LLY will release earnings results for the first quarter, before the opening bell on Thursday, May 1.
Eli Lilly Stock Has The Technicals: Will Q1 Earnings Deliver Fundamentals?
02:06pm, Wednesday, 30'th Apr 2025
Eli Lilly And Co LLY will be reporting its first-quarter earnings on Thursday. Wall Street expects $3.05 in EPS and $12.67 billion in revenues as the company reports before market hours.
Eli Lilly's Stock Is Up 15% This Year, and Here's Why It Could Take Off Even More
05:50am, Wednesday, 30'th Apr 2025
Growth stocks often don't come cheap, especially when their prospects look great, as is the case with Eli Lilly (LLY 1.09%). It is the most valuable healthcare company in the world, with a market cap
S&P 500 (VOO) Live: Trump Administration Blasts Amazon.com, and the S&P 500 Tumbles
04:32pm, Tuesday, 29'th Apr 2025
Live Updates Live Coverage Has Ended S&P 500 Extends Its Winning Streak 4:18 pm The S&P 500 closed up 0.6% for Tuesday, extending its winning streak to six straight days. Trade Talks Keep S&am
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
11:30am, Tuesday, 29'th Apr 2025
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa
Creyon Bio and Lilly Enter into RNA-Targeted Oligo Therapy Development Collaboration
10:07am, Tuesday, 29'th Apr 2025
SAN DIEGO--(BUSINESS WIRE)-- #AIinHealthcare--Creyon Bio, Inc. (“Creyon”) today announced a global licensing and multi-target research collaboration with Eli Lilly and Company (“Lilly”) focuse
